Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Promote Pregnancy Wellness: Data Can Help Guide Pregnancy Management in Lupus

Thomas R. Collins  |  September 10, 2018

AMSTERDAM—Clinicians who are counseling women with systemic lupus erythematosus (SLE) have the benefit of an array of new insights into factors linked with increased risk of pregnancy loss, how SLE therapies affect pregnancy and data on outcomes of children born to mothers with SLE, an expert said in a session at EULAR: the Annual European…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:HYDROXYCHLOROQUINELupus nephritispregnancypregnant womensystemic lupus erythematosus (SLE)

Advocates for Arthritis Fly-In Event Benefits Rheumatology Patients

Kelly Tyrrell  |  September 9, 2018

Pendaar Pooyan was diagnosed with juvenile idiopathic arthritis (JIA) in elementary school. He learned to ask for what he needed: use of a computer in class because of wrist pain and a locker that didn’t require him to bend down so far. And he learned to talk about his disease. This helped make participating for…

Filed under:American College of RheumatologyLegislation & AdvocacyProfessional Topics Tagged with:Advocacy 101Advocates for ArthritisDepartment of Defense (DoD)dual-energy X-ray absorptiometry (DXA)step therapy

Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE

Lara C. Pullen, PhD  |  September 6, 2018

A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:baricitiniborgan damagerashsystemic lupus erythematosus (SLE)

Coding Corner Question: To Bill or Not to Bill an Eval & Management Visit?

From the College  |  August 17, 2018

Scenario 1 History: A 45-year-old male patient with sero-negative rheumatoid arthritis affecting multiple sites, but with no organ or systems involvement, comes for a follow-up visit. The patient reports swelling of the left knee with throbbing left knee pain. He rates the severity of his pain at an 8 on a 10-point scale. The pain…

Filed under:Billing/CodingFrom the CollegePractice Support Tagged with:Billing & Coding

Psoriatic Arthritis Research Continues Hunt for Biomarkers

Thomas R. Collins  |  August 17, 2018

AMSTERDAM—Molecular signatures in synovial tissue that can be gathered through biopsies are a largely untapped resource that could help guide treatment for rheumatic conditions, an expert said at the EULAR: Annual European Congress of Rheumatology. “I’m convinced that looking into synovial tissue provides us with tools to not only understand mechanisms of disease in rheumatoid…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:BiomarkersC-reactive protein (CRP)PsAsynovial biopsies

How Does Down Syndrome Affect Musculoskeletal Health?

How Does Down Syndrome Affect Musculoskeletal Health?

Prasanna Bastola, MBBS, & Daniel A. Albert, MD  |  August 17, 2018

Down syndrome (trisomy 21) is one of the most common chromosomal abnormalities. According to the Genomic Resource Centre of the World Health Organization, each year 3,000–5,000 children are born with this chromosome disorder, and about 250,000 families have at least one member with Down syndrome in the U.S. Down syndrome is caused by numerical aneuploidy,…

Filed under:Conditions Tagged with:Down Syndrome

Study Finds Tocilizumab Could Be Treatment Option for Takayasu Arteritis

Carina Stanton  |  August 17, 2018

For patients with refractory Takayasu arteritis (TAK), glucocorticoids (GCs) are often provided as the initial therapy for treatment. However, GCs are often associated with adverse effects for long-term use; relapse also occurs frequently during GC tapering.1 TAK involves interleukin (IL) 6. Tocilizumab—a recombinant, humanized, anti-IL-6 receptor (IL-6R) monoclonal antibody—was first reported by Nishimoto et al….

Filed under:ConditionsVasculitis Tagged with:ActemraTakayasu arteritis (TAK)tocilizumab

Effects of Obesity on Sustained Remission in Early RA

Arthritis Care & Research  |  August 6, 2018

A new study examined the independent effects of excess weight and obesity on achieving sustained remission in rheumatoid arthritis (RA) patients. Researchers found that within three years of RA diagnosis, overweight and obese patients were significantly less likely to achieve sustained remission than patients with healthy body mass indices (BMIs). Higher BMIs were also associated with persistent disease activity…

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:Arthritis Care & Researchearly RAObesityRemissionRheumatoid Arthritis (RA)

4 Rheumatoid Arthritis Therapy Principles, & New Drug Info

Thomas R. Collins  |  July 19, 2018

CHICAGO—Amid what she called a “dizzying array of choices” for rheumatoid arthritis (RA)—from anti-TNF and anti-IL6-receptor therapies to B cell depletion to new biosimilar options—disease treatment should still revolve around several basic concepts, an expert said at the ACR State-of-the-Art Clinical Symposium in April. Joan Bathon, MD, chief of rheumatology at Columbia University in New…

Filed under:ConditionsRheumatoid Arthritis Tagged with:2018 State of the Art Clinical SymposiumBiosimilarsDisease-modifying antirheumatic drugs (DMARDs)ILDInterstitial Lung Disease

The Impact of Pharma Info vs. Neutral Info on Patients’ Drug Decisions

Catherine Kolonko  |  July 19, 2018

Patients who reviewed an industry-sponsored booklet about a commonly used rheumatoid arthritis drug were twice as likely to choose the proposed therapy as were patients who reviewed similar decision-aid material presented in a neutral manner, according to a recent study. Richard Martin, MD, MA, professor of medicine, rheumatology, at Michigan State University College of Human…

Filed under:Drug UpdatesPatient Perspective Tagged with:patient communicationpatient educationpatient management

  • « Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 106
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences